维普期刊资源整合服务平台（V6.5）

178篇 您的检索式：作者名="Shah NP"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	Dasatinib用于治疗对伊马替尼耐药的Ph染色体阳性白血病显示文摘	Talpaz M Shah NP Kantarjian H 菅鑫妍	2006	中国处方药2006，5，8：	12
2	Effects of milk-derived bioactives:an overview显示文摘	Shah NP	2000	Br J Nutr2000，84，1：	1
3	Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastie leukemia who failed imatinib:results from a phase 3 study显示文摘	Lilly MB Ottmann OG Shah NP	2010	Am J Haematol2010，85，3：	1
4	Endocrine neo- plasm scintigraphy: added value of fusing SPECT/CT images compared with traditionalside-by-side analysis显示文摘	Ingui CJ Shah NP Oates ME	2006	Clin Nucl Med2006，31，11：	1
5	Influence of addition of proteolytic strains of Lactobacillus delbrueckii subsp, bulgaricus to commeracial ABT starter cultures on texture of yoghurt, exopolysaccharide production and survival of bacteria显示文摘	shihata A shah NP	2002	International Dairy Journal2002，12，9：	1
6	Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia显示文摘	SHAH NP	2011	Clin Adv Hematol Oncol2011，9，12：	1
7	Potent, transient inhibi- tion of BCR - ABL with dasatinib 100mg daily achieves rapid and durable cytngenetie responses and high transformationfree survival rates in chronic myeloid leukemia patients with resistance, subopti- mal response or intoleranceintoimatinib显示文摘	Shah NP Dong-wook K Dream HK	2010	Haematologica2010，95，2：	1
8	Bioavailability of isoflavone phytoestrogens in postmenopausal women consuming soy milk fermented with probiotics bifidobacteria显示文摘	Tsangalis D Wilcox G Shah NP	2005	Br J Nutr2005，93，：	1
9	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571)in chronic phase and blast crisis chronic myeloid leukemia 显示文摘	Shah NP Nicoll JM Nagar B	2002	Cancer Cell2002，2，：	1
10	Acid and bile tolerance and cholesterol removal ability of lactobacilli strains显示文摘	LIONG MT SHAH NP	2005	J Dairy Sci2005，88，：	1
11	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia 显示文摘	Shah NP Nicoll JM Nagar B	2002	Cancer Cell2002，2，2：	1
12	Dasatinib versus ima- tinib in newly diagnosed chronic-phase chronic myeloid leukemia 显示文摘	Kantarjian H Shah NP Hoehhaus A	2010	N Engl J Med2010，362，24：	1
13	Multiple < i > BCR - ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib ( STI571) in chronic phase and blast crisis chronic myeloid leukemia 显示文摘	Shah NP Nicoll JM Nagar B	2002	Cancer cell2002，2，2：	1
14	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia显示文摘	Shah NP Nicoll JM Nagar B	2002	Cancer Cell2002，2，2：	1
15	Probiotics-From Metchnikoff to bioactives 显示文摘	Vasiljevic T Shah NP	2008	In Dairy J2008，18，7：	1
16	Release and identification of angiotensin-convert-ing enzyme-inhibitory peptides as influenced by ripening tempera-tures and probiotic adjuncts in Cheddar cheeses显示文摘	Ong L Shah NP	2008	LWT-food sci-ence and technology2008，41，9：	1
17	Clinical resistance to thekinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop显示文摘	Roumiantsev S Shah NP Gorre ME	2002	Proc Natl Acad Sei U S A2002，99，10：	1
18	Probiotie bacteria: selective enumeration and survival in dairy foods显示文摘	SHAH NP	2001	J Dairy Sci2001，83，：	1
19	Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCB-ABL mutations with altered oncogenic potency显示文摘	Shah NP Skaggs BJ Branford S	2007	J Clin Invest2007，117，9：	1
20	:Intermittent target inhi-bition with dasatinib 100 mg once daily preserves efficacy and im-proves tolerability in imatinib resistant and-intolerant chronic-phase chronic myeloid leukemia显示文摘	Shah NP Kantarjian HM Kim DW	2008	J Clin Oncol2008，26，32：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示